SCHEMBL16775672

SCHEMBL16775672

SN1CC=CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL347412 0.57
SCHEMBL1196421 0.56
SCHEMBL13055323 0.55
SCHEMBL9696602 0.55
SCHEMBL5943316 0.55
SCHEMBL763305 0.55
SCHEMBL8271642 0.55
SCHEMBL3614503 0.55
SCHEMBL8508860 0.52
SCHEMBL347420 0.50

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3798214-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2021-03-31 EP disclosed
EP-3647311-A1 RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF Beijing Tide Pharmaceutical Co., Ltd. (CN) 2020-05-06 EP disclosed
WO-2017103670-A1 1H-IMIDAZO[4,5-B]PYRIDINYL AND 2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDINYL HETEROCYCLIC BET BROMODOMAIN INHIBITORS ZENITH EPIGENETICS LID. (CA) 2017-06-22 WO disclosed
US-20150150858-A1 COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER SUNESIS PHARMACEUTICALS, INC. 2015-06-04 US disclosed